They've been losers for nearly 9 years, but Big Pharma might finally be poised for a breakout. And earnings this week may be the catalyst. Schering-Plough (SGP) and Wyeth (WYE) hit tomorrow with Pfizer (PFE) to follow on Friday. Are the big drugmakers going to carry the next leg of this bull market?
Stacey Gilbert, Chief Options Strategist For Susquehanna Financial Group joins the guys for this conversation.
She’s seeing buyers of options taking a bullish position not only going into earnings – but into Jan ’08.
Guy Adami says Stacey is right. He likes Wyeth for its pipeline and for speculation that it could be a merger candidate.
Pete Najarian thinks some large cap pharma has inflated value. He prefers the managed healthcare sector and likes Wellpoint (WLP) and UnitedHealth (UNH) because he believes these companies have more upside.
Stacey adds that she likes Pfizer’s pipeline.
Eric Bolling says Merck (MRK) has the best chart of all the companies in the large cap pharma sector.
Jeff Macke agrees and recommends getting long in the space.
Stacey says investors should buy Pharmaceutical HOLDRS (PPH), which will give them broader exposure to the space.
On APR 18, 2007, the following stocks and commodities mentioned or intended to be mentioned on CNBC’s Fast Money were owned by the Fast Money traders Najarian Owns (AXP), (AAPL), (BAC), (BMY), (C), (CSX),(ENER), (XLF);(JPM), (NOK), (LUV); Bolling Owns (XOM)< (NMX), (ICE), (MPEL), (NMX) Gold, Silver, Natural Gas, Corn; Bolling Is Short Soybeans Stacey Briere Gilbert is Chief Options Strategist/Head of Market Intelligence Research for Susquehanna Financial Group, LLLP. Ms. Gilbert does not cover individual securities, but does recommend trading strategies. An affiliate of Susquehanna Financial Group, LLLP is the NYSE Specialist in XLF.